A.Menarini Singapore PTE. LTD. (Malaysia) has been awarded the Marketing & Communications Initiative of the Year – Malaysia at the prestigious Healthcare Asia Pharma Awards 2025. The accolade recognises the company’s dedicated efforts in raising awareness and promoting early detection of Mild Cognitive Impairment (MCI) through strategic collaboration, education, and community outreach.
With MCI on the rise due to an ageing population, the condition presents a growing concern as it significantly increases the risk of developing dementia. However, low public awareness, stigma, and insufficient healthcare resources continue to hinder timely diagnosis and management. Addressing these gaps, A.Menarini established the MCI Steering Committee, uniting leading experts to build consensus on effective MCI management an effort officially endorsed by recognised medical societies.
To bridge knowledge gaps in primary care, A.Menarini collaborated with the Malaysian Pharmaceutical Association (MPA) and the Malaysian Medical Association (MMA), developing educational modules tailored for general practitioners and pharmacists. These initiatives aimed to empower healthcare providers with the tools and understanding needed to identify and manage MCI early.
A significant breakthrough came with the co-creation of the Visual Cognitive Assessment Test (VCAT) in partnership with ACT4Health, a University of Malaya spin-off. The test improves communication between patients and clinicians, enhancing diagnostic accuracy. Alongside this, an MCI VCAT algorithm was developed to guide structured patient assessments and streamline care pathways.
On the public front, A.Menarini, ACT4Health, and CARiNG Pharmacy launched a campaign offering free VCAT screenings at selected pharmacy outlets. This grassroots effort boosted early detection and reinforced EGB 761 as a recognised treatment option for MCI, ultimately elevating the standard of care in Malaysia.
The Healthcare Asia Pharma Awards, presented by Healthcare Asia Magazine, celebrates excellence and innovation across the pharmaceutical landscape in Asia. A.Menarini’s recognition underscores the company’s unwavering commitment to enhancing patient outcomes and advancing public health.
To view the complete list of winners or to participate in the 2026 awards, visit Healthcare Asia’s official website or contact Julie Anne Nuñez for nomination details.
